Study
PanCuRx Translational Research Initiative
Study ID | Alternative Stable ID | Type |
---|---|---|
EGAS00001002543 | Other |
Study Description
The goal of the PanCuRx TRI is to seek solutions to the high fatality rate of pancreatic adenocarcinoma (PDAC), the most common type of pancreatic cancer, by generating new knowledge about the genetics and biology of the disease, mechanisms of how tumours grow and tailored treatment options.
PDAC is the fourth leading cause of cancer death in Canada and is expected to become the second-leading cause of cancer death within the next decade. The current five-year survival rate of eight per cent is the lowest of all epithelial cancers. There are major clinical challenges to treating the disease, including the fact that PDAC spreads to other parts of the body early so surgical removal of the tumour benefits few patients, that PDAC has proven relatively resistant to systemic therapies such as chemotherapy and that there has been limited benefit from the use of newer molecular targeted agents.
The PanCuRx team has created the world’s first resource of tumour-purified PDAC whole genomes; more than 500 PDAC samples, with combined clinical annotation, have been successfully sequenced ... (Show More)
Study Datasets 14 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001003582 |
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial - RNA-Seq unmapped reads
|
Illumina HiSeq 2500 | 50 |
EGAD00001003584 |
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial - RNA-Seq mapped reads
|
N/A | |
EGAD00001003585 |
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial - WGS mapped reads
|
N/A | |
EGAD00001004548 |
Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases - RNA-Seq mapped and unmapped reads
|
Illumina HiSeq 2500 | 75 |
EGAD00001004551 |
Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases - WGS mapped reads
|
N/A | |
EGAD00001005799 |
Bam and fastq files from RNA-seq of PDAC samples described in Transcription phenotypes of pancreatic cancer are driven by genomic events events during tumour evolution
|
Illumina HiSeq 2500,unspecified | 34 |
EGAD00001006081 |
PURPOSE: To determine the impact of basal-like and classical subtypes in advanced PDAC and to explore GATA6 expression as a surrogate biomarker. EXPERIMENTAL DESIGN: Within the COMPASS trial patients proceeding to chemotherapy for advanced PDAC undergo tumour biopsy for RNA sequencing. Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ ... (Show More)
|
Illumina HiSeq 2500,unspecified | 101 |
EGAD00001006152 |
Bam files from WGS of PDAC samples described in: Transcription phenotypes of pancreatic cancer are driven by genomic events events during tumour evolution
|
N/A | |
EGAD00001006261 |
Bam and fastq files from RNA-seq of PDAC samples used in the PCSI mismatch repair study
|
Illumina HiSeq 2500,unspecified | 4 |
EGAD00001006262 |
Bam files from WGS of PDAC samples used in the PCSI mismatch repair study
|
N/A | |
EGAD00001007571 |
Background and Aims: Homologous recombination deficiency (HRD) in pancreatic ductal adenocarcinoma (PDAC), remains poorly defined beyond germline(g) alterations in BRCA1, BRCA2 and PALB2. Methods: We interrogated whole genome sequencing (WGS) data on 391 patients including 49 carriers of pathogenic variants (PVs) in g_BRCA_ and PALB2. HRD classifiers were applied to the dataset and included: 1) the genomic instability score (GIS) used by Myriad MyChoice HRD assay; 2) substitution base signature ... (Show More)
|
N/A | |
EGAD00001008155 |
Intratumoral heterogeneity is a critical frontier in understanding how the tumor microenvironment (TME) propels malignant progression. Here, we deconvolute the human pancreatic TME through large-scale integration of histology-guided regional multiOMICs with clinical data and patient-derived preclinical models. We discover subTMEs, histologically definable tissue states anchored in fibroblast plasticity, with regional relationships to tumor immunity, subtypes, differentiation, and treatment ... (Show More)
|
Illumina HiSeq 2500,unspecified | 29 |
EGAD00001009409 |
BAM files from RNA-seq of PDAC samples used in the COMPASS hENT1 study
|
1 | |
EGAD00010001811 |
h5 files from 15 single cell PDAC samples described in "Transcription phenotypes of pancreatic cancer are driven by genomic events events during tumour evolution"
|
15 |
Who archives the data?

Publications
Citations
Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...
